

# **Intermuscular Adiposity is Associated with Coronary Microvascular Dysfunction Independently of Body Mass Index and Modifies its Effect on Adverse Cardiovascular Outcomes**

Ana C. Souza, MD, PhD,<sup>1\*</sup> Amelie S. Troschel, MD,<sup>2,3\*</sup> Jan P. Marquardt, MD,<sup>2</sup> Filipe A. Moura, MD, PhD,<sup>1,4</sup> Sanjay Divakaran, MD,<sup>1,4,5</sup> Jon Hainer, BS,<sup>1,5</sup> Ron Blankstein, MD,<sup>1,4,5</sup> Sharmila Dorbala, MD, MPH,<sup>1,4,5</sup> Marcelo F. Di Carli MD,<sup>1,4,5</sup> Florian J. Fintelmann, MD,<sup>2</sup> Viviany R. Taqueti, MD, MPH<sup>1,4,5</sup>

<sup>1</sup>Cardiovascular Imaging Program, Departments of Medicine and Radiology, Brigham and Women's Hospital, Boston, MA; <sup>2</sup>Division of Thoracic Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA; <sup>3</sup>Medical Department II, Klinikum Wolfsburg, Wolfsburg, Germany;

<sup>4</sup>Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA;

<sup>5</sup>Division of Nuclear Medicine and Molecular Imaging, Brigham and Women's Hospital, Boston, MA

\*These authors contributed equally to this work

**Short title:** Intermuscular fat, CMD and cardiovascular risk

*Original Research Article*

Word Count 3226      References 37      Tables 3      Figures 4      Suppl Material 3

Correspondence to:

Viviany R. Taqueti, MD, MPH, Director, Cardiac Stress Laboratory, Brigham and Women's Hospital; 75 Francis St, Boston, MA 02115; tel:617-732-8667; e-mail:vtaqueti@bwh.harvard.edu

## Clinical Perspective

### What is new?

- Intermuscular fat infiltration is associated with coronary microvascular dysfunction (CMD) and adverse cardiovascular outcomes independently of BMI and conventional risk factors.
- Every 1% increase in thoracic fatty muscle fraction conferred an independent 2% increased odds of CMD and a 7% increased risk of adverse cardiovascular events.
- The presence of both coronary microvascular dysfunction and skeletal muscle fat infiltration identified a novel at-risk cardiometabolic phenotype prevalent in patients with ischemia and no obstructive CAD (INOCA).

### What are the clinical implications?

- Obesity-related cardiovascular risk is not well-captured by BMI, especially in those with few traditional risk factors and greater subcutaneous adiposity.
- Skeletal muscle quantity *and* quality are tied to coronary microvascular function and may help to identify cardiometabolic risk beyond traditional measures of adiposity, especially in women.

## Abstract

**Background:** Skeletal muscle (SM) fat infiltration, or intermuscular adipose tissue (IMAT), reflects muscle quality and is associated with inflammation, a key determinant in cardiometabolic disease. Coronary flow reserve (CFR), a marker of coronary microvascular dysfunction (CMD), is independently associated with BMI, inflammation and risk of heart failure, myocardial infarction and death. We sought to investigate the relationship between skeletal muscle quality, CMD and cardiovascular outcomes.

**Methods:** Consecutive patients (N=669) undergoing evaluation for CAD with cardiac stress PET demonstrating normal perfusion and preserved left ventricular ejection fraction were followed over median 6 years for major adverse cardiovascular events (MACE), including death and hospitalization for myocardial infarction or heart failure. CFR was calculated as stress/rest myocardial blood flow and CMD defined as  $CFR < 2$ . Subcutaneous adipose tissue (SAT), SM and IMAT areas ( $cm^2$ ) were obtained from simultaneous PET attenuation correction CTs using semi-automated segmentation at the twelfth thoracic vertebra (T12) level.

**Results:** Median age was 63 years, 70% were female and 46% nonwhite. Nearly half of patients were obese (46%, BMI 30-61) and BMI correlated highly with SAT and IMAT ( $r=0.84$  and  $0.71$ , respectively,  $p < 0.001$ ) and moderately with SM ( $r=0.52$ ,  $p < 0.001$ ). Decreased SM and increased IMAT, but not BMI or SAT, remained independently associated with decreased CFR (adjusted  $p=0.03$  and  $p=0.04$ , respectively). In adjusted analyses, both lower CFR and higher IMAT were associated with increased MACE [HR 1.78 (1.23-2.58) per -1U CFR and 1.53 (1.30-1.80) per +10  $cm^2$  IMAT, adjusted  $p=0.002$  and  $p < 0.0001$ , respectively], while higher SM and

SAT were protective [HR 0.89 (0.81-0.97) per +10 cm<sup>2</sup> SM and 0.94 (0.91-0.98) per +10 cm<sup>2</sup> SAT, adjusted p=0.01 and 0.003, respectively]. Every 1% increase in fatty muscle fraction [IMAT/(SM+IMAT)] conferred an independent 2% increased odds of CMD [CFR<2, OR 1.02 (1.01-1.04), adjusted p=0.04] and a 7% increased risk of MACE [HR 1.07 (1.04-1.09), adjusted p<0.001]. There was a significant interaction between CFR and IMAT, not BMI, such that patients with both CMD and fatty muscle demonstrated highest MACE risk (adjusted p=0.02).

**Conclusion:** Increased intermuscular fat is associated with CMD and adverse cardiovascular outcomes independently of BMI and conventional risk factors. The presence of CMD and skeletal muscle fat infiltration identified a novel at-risk cardiometabolic phenotype.

**Keywords:** obesity; body composition; intermuscular fat; coronary microvascular dysfunction; cardiovascular events; women's heart disease

## Introduction

Overweight or obesity is prevalent in over 71% of US adults<sup>1</sup> and has become one of the most important threats to public health worldwide. Compared to individuals with normal weight, those with obesity, defined as a body mass index (BMI)  $\geq 30$  kg/m<sup>2</sup>, experience cardiovascular disease (CVD) events at an earlier age and have a shorter average life span.<sup>2, 3</sup> Excess adiposity accelerates atherosclerosis and promotes adverse changes in cardiac structure and function through deleterious effects on the myocardium as well as the vasculature, and through obesity-related comorbidities, including hypertension, dyslipidemia and type 2 diabetes mellitus.<sup>4, 5</sup> Although increasing BMI is associated with increasing risk of morbidity and mortality across populations, CVD risk is not uniform for individuals with similar BMI and can vary substantially across sex and racial/ethnic groups. Nonetheless, BMI thresholds continue to guide current clinical diagnosis of obesity and candidacy for interventions with potential to improve CVD outcomes. Besides BMI, other discriminators of cardiovascular risk are needed in individuals at risk for cardiometabolic disease. Imaging technologies such as computed tomography (CT) can be used to assess body composition and distinguish between fat and lean mass directly in vivo via their respective radiodensities, or attenuation, within anatomical compartments.<sup>6</sup>

Recently, intermuscular adipose tissue (IMAT) has emerged as a distinct adipose depot reflecting SM fat infiltration with unique and evolving biological properties. Whereas fatty ‘marbling’ of meat is commercially valued in livestock, IMAT in humans has been associated with insulin resistance and type 2 diabetes.<sup>7, 8</sup> IMAT can be found in most skeletal muscle groups, and while IMAT increases with BMI, it can vary considerably between individuals. Early reports suggest that IMAT has a proinflammatory secretome with increased expression

of IL-6 and TNF, which may affect the metabolic function and insulin sensitivity of neighboring muscle tissue,<sup>9-11</sup> but the impact of IMAT on CVD events is not well understood.

Coronary microvascular dysfunction (CMD), quantified noninvasively using positron emission tomography (PET) as an impaired global coronary flow reserve (CFR <2) with normal myocardial perfusion imaging, is independently associated with elevated BMI<sup>12</sup> and future risk of heart failure, myocardial infarction and death.<sup>13-18</sup> It is also associated with residual inflammation and myocardial stiffness independently of conventional CVD risk factors in patients with cardiometabolic disease.<sup>19,20</sup> We previously demonstrated an independent inverted J-shaped relationship between BMI and CFR such that in obese patients, CFR decreased linearly with increasing BMI (adjusted  $p < 0.0001$ ).<sup>12</sup> We found that CMD was prevalent in obese patients, worsened with increasing BMI and was a better discriminator of CVD risk as compared to BMI. Given the limitations of BMI, we sought to investigate the relationship between IMAT, CMD and cardiovascular outcomes. We hypothesized that measures of skeletal muscle quantity and quality are associated with coronary microvascular dysfunction and modify its effect on CVD events independently of obesity.

## Methods

### Study population

The study population (**Supplemental Figure S1**) included consecutive patients undergoing cardiac stress testing with PET/CT at Brigham and Women's Hospital (Boston, Massachusetts) from 2007 to 2014. The most common indication for PET was the evaluation of chest pain, dyspnea or their combination. Patients with known coronary artery disease (CAD), including a history of previous myocardial infarction or revascularization, heart failure,

severe valvular disease, PET evidence of flow-limiting CAD (defined as a summed stress score  $>2$ ) or abnormal left ventricular ejection fraction (LVEF,  $<40\%$ ) were excluded, as were patients with end-stage disease, including liver, lung or kidney disease, active malignancy or planned bariatric surgery at the time of imaging. Medical history, medication use, laboratory findings, height and weight were ascertained at the time of PET/CT imaging. BMI was calculated as the ratio between weight in kilograms and the square of height in meters. The Chronic Kidney Disease Epidemiology Collaboration equation was used to determine eGFR. The study was approved by the Mass General Brigham Healthcare Institutional Review Board and performed in accordance with institutional guidelines.

### **Positron emission tomography imaging**

Patients were imaged with a whole-body PET/CT scanner (Discovery RX or STE LightSpeed 64, GE Healthcare, Milwaukee, Wisconsin) using  $^{82}\text{Rb}$  and  $^{13}\text{N}$ -ammonia as flow radiotracers at rest and following pharmacological stress. Patients were instructed to avoid caffeine or methylxanthine-containing substances 24 hours before the scan. Rest LVEF was obtained from gated myocardial perfusion images processed with commercially available software (Corridor4DM, INVIA Medical Imaging Solutions; Ann Arbor, Michigan). Semiquantitative visual interpretation was performed using a standard 17-segment, 5-point scoring system to determine summed rest, stress and difference scores, reflecting scar, ischemia plus scar, or ischemia, respectively. Absolute global myocardial blood flow (MBF, ml/min/g) was measured at rest and peak vasodilator-induced hyperemia and dynamic images were fitted into a validated two-compartment kinetic model as previously described.<sup>22</sup> CFR was obtained as the ratio of global stress to rest MBF.

## CT-derived body composition analysis

Thoracic body composition metrics, including cross-sectional areas (in cm<sup>2</sup>) of subcutaneous adipose tissue (SAT), skeletal muscle (SM), and intermuscular adipose tissue (IMAT), were measured at the level of the twelfth vertebra (T12) on non-contrast axial CT images obtained for attenuation correction during standard cardiac PET/CT imaging. Studies with artifacts related to patient positioning or image acquisition precluding soft tissue assessment at this level were excluded (**Supplemental Figure S1**). SAT, SM and IMAT were quantified using semi-automated threshold-based segmentation in 3DSlicer (version 4.10.1, <https://www.slicer.org/>) by a trained reader (AST) blinded to study details. Tissue-specific Hounsfield units (HU) were used for skeletal muscle (-29 to +150 HU) and adipose tissue (-190 to -30 HU) as previously described.<sup>23, 24</sup> Boundaries of each compartment were verified with excellent intra-reader class correlations ( $\geq 0.997$ ). Randomly selected samples were re-segmented by independent readers (JPM, FJF) blinded to patient details with excellent inter-reader class correlations ( $\geq 0.972$ ). All body composition analyses were blinded to clinical, PET and outcomes data.

## Outcomes

Patients were followed over a median 5.8 (Q1-Q3 3.2–7.1) years for the occurrence of a primary endpoint composite of death, hospitalization for nonfatal myocardial infarction (MI) or heart failure (HF). Time to first event was analyzed. Ascertainment of clinical endpoints was determined by blinded committee adjudication of the longitudinal medical record, the Mass General Brigham Healthcare Research Patient Data Registry, the National Death Index, mail surveys, and telephone calls. To be classified as hospitalization for nonfatal MI or HF,



discharge with the corresponding primary diagnosis was required, and only events meeting the universal definition of MI<sup>25</sup> or prespecified criteria for clinical signs, symptoms and escalation of therapy for HF, respectively, were adjudicated as such. All hospitalization events occurred >30 days following PET imaging.

## Statistical analyses

Baseline characteristics are presented as rates with percentages (%) for categorical variables and medians with interquartile ranges (Q1-Q3) for continuous variables. We used the Fisher's exact test and the Wilcoxon rank-sum test to assess for differences in categorical and continuous baseline characteristics, respectively. CMD was defined as CFR <2, a prognostically important cutpoint associated with worse cardiovascular outcomes in patients undergoing evaluation for suspected CAD,<sup>27,28</sup> and approximated the median CFR of the clinical cohort. Spearman's correlation was used to describe the association between the continuous variables of BMI and thoracic body composition metrics SAT, IMAT and SM. Fatty muscle fraction (FMF, %) was defined as  $IMAT/(SM+IMAT)*100$ .

Linear regression was used to assess for independent relationships between CFR and body composition metrics. Candidate variables tested included demographic characteristics, medical history and medication use, laboratory findings and noninvasive imaging parameters, with the most clinically important covariates or significant univariable associations included in the multivariable model. To avoid overfitting, demographic and medical history variables (age, sex, anginal symptoms, hypertension, dyslipidemia, diabetes, tobacco use, family history of premature CAD, BMI >27 kg/m<sup>2</sup>, and estrogen status) were incorporated into multivariable modeling using a validated pretest clinical risk score for diagnosing CAD (with values 0-8, 9-

15, and 16-24 indicating low, intermediate, and high pretest risk, respectively), as previously described.<sup>29</sup> The final multivariable model included the pretest clinical score, nonwhite race, BMI, eGFR<60 ml/min/1.73 m<sup>2</sup>, LVEF, SAT, SM and IMAT or FMF. These variables were also incorporated into a logistic regression model to quantify the association between FMF and CMD.

Cumulative event-free survival curves for the composite endpoint of death or hospitalization for nonfatal MI or HF, were compared across categories of CMD and obesity or IMAT median using the log-rank test. Cox proportional hazards models were used to examine for multivariable-adjusted associations of thoracic body composition, CFR and events. Univariate associations were tested and sequential Cox models controlled for effects of clinically important covariates: Model 1 was adjusted for traditional risk factors, including pretest clinical score, race, eGFR, LVEF and BMI, with sequential addition of body composition metrics and CFR to Models 2 and 3, respectively. Nested models were compared with the likelihood ratio test, and the Akaike information criterion was assessed to avoid overfitting. A linear interaction term for CFR and IMAT or FMF was tested for significance in the final adjusted model. The proportional hazards assumption was confirmed for each model using cumulative martingale residuals.

To further investigate the presence of effect modification between CMD and IMAT, Poisson regression was performed to compute adjusted annualized rates of events across categories of CMD and IMAT median after adjustment for pretest clinical score, SM and SAT areas. Model fit was assessed with the goodness-of-fit  $\chi^2$  test, with a nonsignificant result indicating adequate fit. A p-value of <0.05 was considered to indicate statistical significance

and all tests were two-sided. Statistical analyses were performed using SAS (version 9.4, SAS Institute Inc., Cary, NC) and SPSS (version 28.0, IBM Corp, Armonk, NY).

## Results

### Baseline Characteristics

The distribution of baseline characteristics is shown in **Table 1**. The median age of patients in the overall cohort was 62.6 (53.7-71.6) years, 69.8% were women and 46.2% were nonwhite. Approximately 45.9% of patients were obese (BMI 30-61 kg/m<sup>2</sup>), with 21.7% of the cohort classified as having class I obesity (BMI 30-34.9 kg/m<sup>2</sup>), 13.1% as class II obesity (BMI 35-39.9 kg/m<sup>2</sup>) and 11.1% as class III obesity (BMI ≥40 kg/m<sup>2</sup>). Hypertension and dyslipidemia were prevalent comorbidities present in 72.6% and 58.4% of patients, respectively, and 25.6% of patients had diabetes. Median LVEF was 63% (57-70) and 43.0% of patients had CMD, with median coronary flow reserve of 2.1 (1.7-2.6) reflecting median peak stress and rest myocardial blood flow values of 2.3 (1.8-2.9) and 1.1 (0.8-1.4) ml/min/g, respectively. Compared with the nonobese, obese patients had higher median indices of SAT (248.7 vs. 101.5 cm<sup>2</sup>), SM (95.6 vs. 78.9 cm<sup>2</sup>) and IMAT (20.4 vs. 6.5 cm<sup>2</sup>, p<0.001 for all), and similar distributions of CFR. BMI correlated highly with SAT and IMAT (r=0.84 and 0.71, respectively, p<0.001) and moderately with SM (r=0.52, p<0.001) (**Figure 1, Supplemental Figure S2**). Representative patients of similar demographics and BMI with variable thoracic body composition metrics and CFR values are shown in **Figure 2**.

### Association Between Thoracic Body Composition and Coronary Flow Reserve

In univariable linear regression analysis, increasing BMI was inversely associated with CFR [ $\beta$ (se)=-0.07(0.03), p=0.04 for +10 kg/m<sup>2</sup> BMI], as was increasing SAT and IMAT [ $\beta$ (se)=-

0.007(0.002) and -0.053(0.016),  $p=0.003$  and  $0.001$  for  $+10 \text{ cm}^2$  SAT and IMAT areas, respectively] (**Table 2**). After adjustment for clinical covariates and body composition metrics, decreasing SM and increasing IMAT, but not BMI or SAT, remained independently associated with worse CFR [ $\beta(\text{se})=0.027(0.013)$  and  $-0.047(0.023)$ , adjusted  $p=0.03$  and  $0.04$  for  $+10 \text{ cm}^2$  SM and IMAT areas, respectively] (**Table 2**). Findings were confirmed using FMF [ $\beta(\text{se})=-0.008(0.004)$ , adjusted  $p=0.02$  for  $+1\%$  FMF]. In univariable and multivariable-adjusted logistic regression analyses, every 1% increase in FMF was associated with a 2% increased odds of CMD [OR 1.02 (1.01-1.04), unadjusted  $p=0.008$  and adjusted  $p=0.04$ ] defined as  $\text{CFR} < 2$ .

### **Thoracic Body Composition, Coronary Flow Reserve and Adverse Events**

Over a median follow-up of 5.8 (3.2-7.1) years, 98 patients met the composite endpoint of death and hospitalization for MI or HF, including 54 deaths (**Supplemental Table S1**). In univariable analysis, CFR and IMAT were significantly associated with major adverse events (HR 1.81, 95%CI 1.28-2.56 per -1U CFR,  $p=0.001$  and HR 1.21, 95%CI 1.09-1.35 per  $+10 \text{ cm}^2$  IMAT,  $p<0.001$ , respectively) (**Table 3**). The addition of body composition metrics SAT, SM and IMAT into a multivariable model of clinically important covariates, including pretest clinical score, race, BMI, eGFR and LVEF led to improvement in model statistics (Global Chi-square 65.4 vs 26.8 for Model 2 vs 1, respectively,  $p<0.001$ ), as did the sequential addition of CFR (Global Chi-square 74.5 vs 65.4 for Model 3 vs 2, respectively,  $p<0.001$   $p<0.001$  for Model 3 vs 2) (**Table 3**). In the final adjusted model, both lower CFR and higher IMAT were associated with increased events [HR 1.78 (1.23-2.58) per -1U CFR and 1.53 (1.30-1.80) per  $+10 \text{ cm}^2$  IMAT, adjusted  $p=0.002$  and  $p\leq 0.0001$ , respectively], while higher SM and SAT were protective [HR 0.89 (0.81-0.97) per  $+10 \text{ cm}^2$  SM and 0.94 (0.91-0.98) per  $+10 \text{ cm}^2$  SAT,

adjusted  $p=0.01$  and  $0.003$ , respectively]. There was a significant interaction between CFR and IMAT such that patients with both CMD and fatty muscle demonstrated the highest risk of events (adjusted  $p$  for interaction= $0.02$ ). Every 1% increase in fatty muscle fraction conferred an independent 7% increased risk of major adverse events [HR 1.07 (1.04-1.09), adjusted  $p<0.001$ ], and modified the effect of CMD on outcomes (adjusted  $p$  for interaction= $0.04$ ).

### **Obesity, Intermuscular Adiposity, Coronary Microvascular Dysfunction and Outcomes**

To visualize the impact of effect modification of intermuscular adipose tissue on coronary microvascular dysfunction and cardiovascular events, we stratified results by CMD and obesity (**Figures 3A, 3B**) or IMAT median (**Figures 3C, 3D**). In adjusted analysis, patients with CMD with or without obesity experienced the highest cumulative rate of events (adjusted  $p<0.001$ , **Figure 3B**). Elevated BMI did not further stratify risk among patients with CMD (**Figures 3B, 4A**). In contrast, only those patients with both CMD and high IMAT experienced the highest rate of adverse events (adjusted  $p<0.001$ , **Figures 3D, 4B**), with an adjusted annualized rate of events of 5.1% (adjusted  $p=0.02$ ).

### **Discussion**

In this work, we leveraged advances in noninvasive imaging to demonstrate a novel relationship between IMAT, CMD and cardiovascular outcomes. First, we found that lower skeletal muscle quantity and quality was associated with coronary microvascular dysfunction, independently of conventional risk factors. Every 1% increase in fatty muscle fraction conferred an independent 2% increased odds of CMD. Second, in adjusted analyses for outcomes, we showed that both higher IMAT and lower CFR were associated with increased risk of CVD

events, while higher SM and SAT were protective. Every 1% increase in fatty muscle fraction conferred a 7% increased risk of CVD events. Third, the presence of elevated IMAT, not BMI, modified the effect of CMD on outcomes such that patients with both CMD and fatty muscle, not obesity, demonstrated the highest risk of CVD events. Our data support that thoracic skeletal muscle quantity *and* quality are tied to coronary microvascular function and may help to identify at-risk cardiometabolic phenotypes beyond traditional measures of adiposity.

These findings may hold special relevance for the common clinical demographic represented here, namely women and patients with ischemia and no obstructive CAD (INOCA). Obesity-related CVD risk is not well-captured by BMI, especially in women.<sup>30</sup> While increased thoracic IMAT was independently associated with worse CVD events, higher thoracic SM and, to a lesser extent, SAT demonstrated a protective effect. This underscores that in INOCA patients, assessments of BMI and traditional adiposity – which largely reflect lower-risk SAT – are likely to be *insufficient* to appropriately stratify CVD risk. Our findings are clinically relevant and may help to better discern CVD risk among otherwise similar patients, especially younger, female individuals with fewer traditional risk factors and high prevalence of overweight/obesity. **Figures 2A and 2B** demonstrate thoracic body composition results in 2 middle-aged Hispanic women with class II obesity. Despite similar age and BMI, normal renal function, LVEF and myocardial perfusion, patient (B) has increased IMAT and decreased CFR as compared to patient (A), and thus may be at a significantly increased risk of CVD events.

Described not long ago, IMAT reflects an ectopic adipose tissue depot that is interspersed among skeletal muscle fibers residing within the boundary of the muscle fascia.<sup>8</sup> Considered a marker of overall muscle quality, it has been associated with systemic inflammation, insulin resistance, the metabolic syndrome, and coronary artery calcification in a

manner comparable to visceral adipose tissue.<sup>11, 31, 32</sup> We recently reported on the independent associations between residual inflammation, abnormal coronary flow reserve and impaired myocardial strain in a cohort of clinical trial patients with cardiometabolic disease and otherwise well-controlled CVD risk factors and preserved cardiac function.<sup>19</sup> We found that individuals with impaired CFR demonstrated the strongest association between markers of heart failure and inflammation, building on prior work identifying abnormal global CFR and CMD as robust markers of future risk of heart failure hospitalization in patients with preserved LVEF.<sup>14-16</sup> HFpEF is prevalent in obese patients and often preceded by exercise intolerance, which may reflect limitations in skeletal muscle related to functional and structural impairments also common to the myocardium, including reduced oxidative capacity, microvascular dysfunction, capillary rarefaction and fibrosis.<sup>33-35</sup>

The expansion of IMAT is thought to promote an adverse muscle phenotype associated with metabolic derangements, including impaired bioenergetics, mitochondrial dysfunction, and increased catabolism with loss of lean muscle mass.<sup>8</sup> Emerging data suggest that the human IMAT secretome is highly immunogenic and inflammatory relative to that of SAT or even VAT depots in individuals with obesity, and may alter immune cell trafficking to neighboring muscle in a manner that may be critical to regional glucose homeostasis.<sup>11</sup> Taken together, these findings support the hypothesis that common systemic factors involving inflammation and altered glucose metabolism may promote parallel insults to myocardial and skeletal muscle beds, which may manifest as microvascular dysfunction and intramuscular fat infiltration, respectively, and ultimately contribute to adverse CVD events, including HFpEF outcomes.

Our study has important limitations including its observational, single-center design. Despite the use of multivariable-adjusted models and confirmatory testing showing robust data

results, residual confounding may persist. Although we leveraged low-dose CTs, which were routinely obtained with clinical cardiac PET studies for the purpose of attenuation correction, we were able to demonstrate excellent segmentation quality assurance, and the ability to obtain concurrent imaging in these patients represents an important strength of this study. Because these were thoracic studies, we focused our cross-sectional assessments at the level of T12 for thoracic body composition analysis. As such, results may differ when compared to abdominal body composition results obtained from the lumbar spine level,<sup>36</sup> and visceral adipose tissue could not be accurately quantified (although we would expect it to have a less important role in this female-predominant cohort since women have significantly lower visceral and higher subcutaneous adiposity as compared with men<sup>30</sup>). Since cardiac PET is performed using vasodilator stress, no exercise testing results were available. As only patients with normal visual myocardial perfusion and no evidence of flow-limiting CAD were included, the patient cohort was predominantly female, although findings are generalizable to an INOCA population. Relative to less accurate or more cumbersome methods for body composition analysis,<sup>37</sup> opportunistic CT used in this manner may provide personalized prognostic information without added cost or radiation exposure, and is poised to grow with rapid developments in artificial intelligence and machine learning. Future studies assessing the impact of therapeutic strategies, such as supervised exercise and nutritional, medical and/or surgical weight loss interventions on skeletal muscle quality and CMD outcomes are warranted.

## **Conclusion**



In patients without flow-limiting CAD, increased intermuscular fat is associated with CMD and adverse cardiovascular outcomes independently of BMI and conventional risk factors. The presence of CMD and skeletal muscle fat infiltration identified a novel at-risk cardiometabolic phenotype.

### **Sources of Funding**

This research was supported by a Lemann Cardiovascular Research Fellowship (ACS); and the Gilead Sciences Research Scholars Program in Cardiovascular Disease and NIH K23HL135438 (VRT).

### **Disclosures**

SDo reports research grants from Pfizer, Attralus, and GE Healthcare, and consulting fees from Janssen, Pfizer, GE Healthcare. MDC reports research grants from Gilead Sciences and Spectrum Dynamics, and consulting fees from Bayer and Janssen. FJF holds a related patent (US11322259B2, WO2019051358A1). All other authors report no relevant disclosures.

## References

1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Fugar S, Generoso G, Heard DG, Hiremath S, Ho JE, Kalani R, Kazi DS, Ko D, Levine DA, Liu J, Ma J, Magnani JW, Michos ED, Mussolino ME, Navaneethan SD, Parikh NI, Poudel R, Rezk-Hanna M, Roth GA, Shah NS, St-Onge MP, Thacker EL, Virani SS, Voeks JH, Wang NY, Wong ND, Wong SS, Yaffe K, Martin SS, American Heart Association Council on E, Prevention Statistics C and Stroke Statistics S. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. *Circulation*. 2023;147:e93-e621.
2. Powell-Wiley TM, Poirier P, Burke LE, Despres JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP, American Heart Association Council on L, Cardiometabolic H, Council on C, Stroke N, Council on Clinical C, Council on E, Prevention and Stroke C. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2021;143:e984-e1010.
3. Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, Sweis RN and Lloyd-Jones DM. Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. *JAMA cardiology*. 2018;3:280-287.
4. Kenchiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB and Vasan RS. Obesity and the risk of heart failure. *N Engl J Med*. 2002;347:305-13.
5. McGill HC, Jr., McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, Strong JP and Pathobiological Determinants of Atherosclerosis in Youth Research G. Obesity accelerates the progression of coronary atherosclerosis in young men. *Circulation*. 2002;105:2712-8.
6. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, Heymsfield SB and Heshka S. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. *Journal of applied physiology*. 2004;97:2333-8.
7. Goodpaster BH, Krishnaswami S, Resnick H, Kelley DE, Haggerty C, Harris TB, Schwartz AV, Kritchevsky S and Newman AB. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. *Diabetes Care*. 2003;26:372-9.
8. Goodpaster BH, Bergman BC, Brennan AM and Sparks LM. Intermuscular adipose tissue in metabolic disease. *Nat Rev Endocrinol*. 2022.
9. Li M, Wu H, Wang T, Xia Y, Jin L, Jiang A, Zhu L, Chen L, Li R and Li X. Co-methylated genes in different adipose depots of pig are associated with metabolic, inflammatory and immune processes. *Int J Biol Sci*. 2012;8:831-7.
10. Sachs S, Zarini S, Kahn DE, Harrison KA, Perreault L, Phang T, Newsom SA, Strauss A, Kerege A, Schoen JA, Bessesen DH, Schwarzmayr T, Graf E, Lutter D, Krumsiek J, Hofmann SM and Bergman BC. Intermuscular adipose tissue directly modulates skeletal muscle insulin sensitivity in humans. *Am J Physiol Endocrinol Metab*. 2019;316:E866-E879.
11. Kahn D, Macias E, Zarini S, Garfield A, Zemski Berry K, Gerszten R, Schoen J, Cree-Green M and Bergman BC. Quantifying the inflammatory secretome of human intermuscular adipose tissue. *Physiol Rep*. 2022;10:e15424.
12. Bajaj NS, Osborne MT, Gupta A, Tavakkoli A, Bravo PE, Vita T, Bibbo CF, Hainer J, Dorbala S, Blankstein R, Bhatt DL, Di Carli MF and Taqueti VR. Coronary Microvascular Dysfunction and Cardiovascular Risk in Obese Patients. *J Am Coll Cardiol*. 2018;72:707-717.

13. Taqueti VR, Everett BM, Murthy VL, Gaber M, Foster CR, Hainer J, Blankstein R, Dorbala S and Di Carli MF. Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease. *Circulation*. 2015;131:528-35.
14. Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, Hainer J, Bibbo CF, Dorbala S, Blankstein R and Di Carli MF. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. *Eur Heart J*. 2018;39:840-849.
15. Taqueti VR, Shaw LJ, Cook NR, Murthy VL, Shah NR, Foster CR, Hainer J, Blankstein R, Dorbala S and Di Carli MF. Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease. *Circulation*. 2017;135:566-577.
16. Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, Dorbala S, Blankstein R and Di Carli MF. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. *Circulation*. 2015;131:19-27.
17. Zhou W, Brown JM, Bajaj NS, Chandra A, Divakaran S, Weber B, Bibbo CF, Hainer J, Taqueti VR, Dorbala S, Blankstein R, Adler D, O'Gara P and Di Carli MF. Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure. *Eur Heart J*. 2020;41:2366-2375.
18. Vita T, Murphy DJ, Osborne MT, Bajaj NS, Keraliya A, Jacob S, Diaz Martinez AJ, Nodoushani A, Bravo P, Hainer J, Bibbo CF, Steigner ML, Taqueti VR, Skali H, Blankstein R, Di Carli MF and Dorbala S. Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT. *Radiology*. 2019;291:330-337.
19. Taqueti VR, Shah AM, Everett BM, Pradhan AD, Piazza G, Bibbo C, Hainer J, Morgan V, Carolina do AHdSA, Skali H, Blankstein R, Dorbala S, Goldhaber SZ, Le May MR, Chow BJW, deKemp RA, Hage FG, Beanlands RS, Libby P, Glynn RJ, Solomon SD, Ridker PM and Di Carli MF. Coronary Flow Reserve, Inflammation, and Myocardial Strain: The CIRT-CFR Trial. *JACC Basic Transl Sci*. 2023;8:141-151.
20. Taqueti VR and Ridker PM. Inflammation, coronary flow reserve, and microvascular dysfunction: moving beyond cardiac syndrome X. *JACC Cardiovasc Imaging*. 2013;6:668-71.
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J and Ckd EPI. A new equation to estimate glomerular filtration rate. *Annals of internal medicine*. 2009;150:604-12.
22. El Fakhri G, Kardan A, Sitek A, Dorbala S, Abi-Hatem N, Lahoud Y, Fischman A, Coughlan M, Yasuda T and Di Carli MF. Reproducibility and accuracy of quantitative myocardial blood flow assessment with (82)Rb PET: comparison with (13)N-ammonia PET. *J Nucl Med*. 2009;50:1062-71.
23. Bridge CP, Best TD, Wrobel MM, Marquardt JP, Magudia K, Javidan C, Chung JH, Kalpathy-Cramer J, Andriole KP and Fintelmann FJ. A Fully Automated Deep Learning Pipeline for Multi-Vertebral Level Quantification and Characterization of Muscle and Adipose Tissue on Chest CT Scans. *Radiol Artif Intell*. 2022;4:e210080.
24. Troschel AS, Troschel FM, Fuchs G, Marquardt JP, Ackman JB, Yang K and Fintelmann FJ. Significance of Acquisition Parameters for Adipose Tissue Segmentation on CT Images. *AJR Am J Roentgenol*. 2021;217:177-185.

25. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD and Executive Group on behalf of the Joint European Society of Cardiology /American College of Cardiology /American Heart Association /World Heart Federation Task Force for the Universal Definition of Myocardial I. Fourth Universal Definition of Myocardial Infarction (2018). *Circulation*. 2018;138:e618-e651.
26. Redfield MM. Heart Failure with Preserved Ejection Fraction. *N Engl J Med*. 2016;375:1868-1877.
27. Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, Kaski JC, Bairey Merz CN and Coronary Vasomotion Disorders International Study G. International standardization of diagnostic criteria for microvascular angina. *Int J Cardiol*. 2018;250:16-20.
28. Taqueti VR and Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2018;72:2625-2641.
29. Morise AP, Haddad WJ and Beckner D. Development and validation of a clinical score to estimate the probability of coronary artery disease in men and women presenting with suspected coronary disease. *The American journal of medicine*. 1997;102:350-6.
30. Kammerlander AA, Lyass A, Mahoney TF, Massaro JM, Long MT, Vasan RS and Hoffmann U. Sex Differences in the Associations of Visceral Adipose Tissue and Cardiometabolic and Cardiovascular Disease Risk: The Framingham Heart Study. *Journal of the American Heart Association*. 2021;10:e019968.
31. Yim JE, Heshka S, Albu J, Heymsfield S, Kuznia P, Harris T and Gallagher D. Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk. *International journal of obesity*. 2007;31:1400-5.
32. Terry JG, Shay CM, Schreiner PJ, Jacobs DR, Jr., Sanchez OA, Reis JP, Goff DC, Jr., Gidding SS, Steffen LM and Carr JJ. Intermuscular Adipose Tissue and Subclinical Coronary Artery Calcification in Midlife: The CARDIA Study (Coronary Artery Risk Development in Young Adults). *Arteriosclerosis, thrombosis, and vascular biology*. 2017;37:2370-2378.
33. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ and Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. *Circulation*. 2015;131:550-9.
34. Pandey A, LaMonte M, Klein L, Ayers C, Psaty BM, Eaton CB, Allen NB, de Lemos JA, Carnethon M, Greenland P and Berry JD. Relationship Between Physical Activity, Body Mass Index, and Risk of Heart Failure. *J Am Coll Cardiol*. 2017;69:1129-1142.
35. Molina AJ, Bharadwaj MS, Van Horn C, Nicklas BJ, Lyles MF, Eggebeen J, Haykowsky MJ, Brubaker PH and Kitzman DW. Skeletal Muscle Mitochondrial Content, Oxidative Capacity, and Mfn2 Expression Are Reduced in Older Patients With Heart Failure and Preserved Ejection Fraction and Are Related to Exercise Intolerance. *JACC Heart failure*. 2016;4:636-45.
36. Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL and Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. *Sci Rep*. 2018;8:11369.
37. Zhang L, Bartz TM, Santanasto A, Djousse L, Mukamal KJ, Forman DE, Hirsch CH, Newman AB, Gottdiener JS and Kizer JR. Body Composition and Incident Heart Failure in Older Adults: Results From 2 Prospective Cohorts. *Journal of the American Heart Association*. 2022;11:e023707.

## Figure Legends

**Figure 1.** Thoracic body composition compartments and relationship to body mass index, BMI. (A) Distribution of BMI in the study population. (B) Example of CT slice selection at the twelfth thoracic vertebra (T12) level and segmentation of subcutaneous adipose tissue (SAT, green), skeletal muscle (SM, blue) and intermuscular adipose tissue (IMAT, red) areas. Relationship between BMI and SAT (C), SM (D), and IMAT (E).

**Figure 2.** Characterization of thoracic body composition at the twelfth thoracic vertebra (T12) level in representative patients (A, B) of similar age, sex, race and BMI with normal renal function, LVEF and myocardial perfusion. Relative to patient (A), patient (B) demonstrated decreased SAT and increased SM and IMAT areas, also with CFR <2, consistent with CMD. BMI: body mass index; LVEF: left ventricular ejection fraction; SAT: subcutaneous adipose tissue; SM: skeletal muscle; IMAT: intermuscular adipose tissue; CFR: coronary flow reserve; CMD: coronary microvascular dysfunction

**Figure 3.** Unadjusted (A, C) and adjusted (B, D) freedom from major adverse events by CMD and obesity (A, B) or IMAT median (C, D). Major adverse events include death and hospitalization for nonfatal myocardial infarction or heart failure. CMD: coronary microvascular dysfunction, coronary flow reserve <2; obesity, body mass index  $\geq 30$ ; IMAT: intermuscular adipose tissue, high  $\geq 11.5 \text{ cm}^2$

\*Adjusted for pretest clinical score, race, estimated glomerular filtration rate <60, left ventricular ejection fraction, skeletal muscle and subcutaneous adipose tissue areas

† p-value refers to interaction between coronary flow reserve and IMAT continuous variables

**Figure 4.** Adjusted annualized rate of major adverse events by CMD and obesity (A) or IMAT median (B). Major adverse events include death and hospitalization for nonfatal myocardial infarction or heart failure. Poisson regression was adjusted for pretest clinical score, skeletal muscle and subcutaneous adipose tissue areas. CMD: coronary microvascular dysfunction, coronary flow reserve <2; obesity, body mass index  $\geq 30$ ; IMAT: intermuscular adipose tissue, high  $\geq 11.5 \text{ cm}^2$



**Table 1.** Baseline Characteristics of the Study Population

Characteristic	Overall (N=669)	Obese*		P-value†
		No (n=362)	Yes (n=307)	
<b>Demographics</b>				
Age (years)	62.6 (53.7-71.6)	64.9 (55.1-74.2)	60.1 (52.1-67.1)	<0.001
Female (%)	467 (69.8%)	236 (65.2%)	231 (75.2%)	0.005
Nonwhite race (%)	309 (46.2%)	146 (40.3%)	163 (53.1%)	0.001
Body mass index (kg/m <sup>2</sup> )	29.2 (25.1-34.7)	25.6 (23.1-27.8)	35.4 (32.3-39.8)	<0.001
Pretest clinical score‡	11 (8-13)	11.0 (8.0-13.8)	10.0 (8.0-14.0)	0.56
<b>Medical history</b>				
Hypertension (%)	486 (72.6%)	231 (63.8%)	255 (83.1%)	<0.001
Dyslipidemia (%)	391 (58.4%)	202 (55.8%)	189 (61.6%)	0.14
Diabetes (%)	171 (25.6%)	57 (15.7%)	114 (37.1%)	<0.001
Family history of CAD (%)	195 (29.1%)	89 (24.6%)	106 (34.5%)	0.006
Current tobacco use (%)	56 (8.4%)	31 (8.56%)	25 (8.14%)	0.89
<b>Medication use</b>				
Aspirin (%)	353 (52.8%)	199 (55.0%)	154 (50.2%)	0.24
Beta-blocker (%)	289 (43.2%)	145 (40.1%)	144 (46.9%)	0.09
Angiotensin inhibitor (%)	197 (29.4%)	88 (24.3%)	109 (35.5%)	0.002
Statin (%)	343 (51.3%)	177 (48.9%)	166 (54.1%)	0.19
Oral hypoglycemic (%)	80 (12%)	24 (6.63%)	56 (18.2%)	<0.001
Insulin (%)	71 (10.6%)	18 (4.97%)	53 (17.3%)	<0.001
<b>Laboratory values</b>				
Creatinine (mg/dL)	0.83 (0.72-0.96)	0.8 (0.7-1.0)	0.8 (0.7-0.9)	0.24
eGFR (ml/min/1.73 m <sup>2</sup> )	84.3 (70.1-96.7)	82.1 (70.4-93.8)	87.1 (70.2-98.6)	0.02
<b>CT body composition measures</b>				
Subcutaneous adipose tissue (SAT, cm <sup>2</sup> )	155.4 (92.7-246.8)	101.5 (69.3-139.9)	248.7 (187.9-317.8)	<0.001
Skeletal muscle (SM, cm <sup>2</sup> )	87.7 (73.5-106.2)	78.9 (67.8-98.7)	95.6 (82.4-114.5)	<0.001
Intermuscular adipose tissue (IMAT, cm <sup>2</sup> )	11.5 (5.6-22.7)	6.5 (4.0-11.3)	20.4 (13.2-34.2)	<0.001
Fatty muscle fraction (FMF, %)	11.6 (6.3-19.1)	7.5 (4.6-12.7)	18.0 (11.7-25.2)	<0.001
<b>PET imaging parameters</b>				
Left ventricular ejection fraction (%)	63 (57-69.5)	63.0 (57.2-70.0)	63.0 (56.0-68.0)	0.46
Rest myocardial blood flow (mL/min/g)	1.1 (0.8-1.4)	1.1 (0.9-1.5)	1.0 (0.8-1.3)	<0.001
Stress myocardial blood flow (mL/min/g)	2.3 (1.8-2.9)	2.5 (2.0-3.1)	2.1 (1.6-2.6)	<0.001
Coronary flow reserve	2.1 (1.7-2.6)	2.1 (1.7-2.6)	2.1 (1.6-2.5)	0.07

Continuous variables are presented as medians (Q1-Q3) and categorical variables as (%).

\*Obese is defined as body mass index  $\geq 30$ .

†The P-value is for the comparison between obese groups and is based on the Fisher exact test for categorical variables and the Wilcoxon rank sum test for continuous variables.

‡ Pretest clinical score integrates age, sex, presence of hypertension, dyslipidemia, diabetes mellitus, body mass index  $>27 \text{ kg/m}^2$ , estrogen status, smoking history, family history, and angina history into a pretest probability of CAD in patients presenting for stress imaging with symptoms of suspected CAD. Risk: low (0–8), intermediate (9–15), and high ( $>15$ ).<sup>29</sup>

CAD, coronary artery disease; CT, computed tomography; eGFR, estimated glomerular filtration rate; PET, positron emission tomography

**Table 2.** Univariable and Multivariable-adjusted Associations of Thoracic Body Composition and CFR

	Univariable		Multivariable*	
	$\beta$ (se)	P-value	$\beta$ (se)	P-value
Pretest clinical score	-0.016 (0.006)	0.01	-0.017 (0.006)	0.008
Nonwhite race	0.041 (0.051)	0.42	0.039 (0.052)	0.46
eGFR<60 ml/min/1.73 m <sup>2</sup>	-0.020 (0.085)	0.81	0.063 (0.086)	0.47
LVEF (+10%)	-0.058 (0.028)	0.04	-0.040 (0.029)	0.17
BMI (+10 kg/m <sup>2</sup> )	-0.069 (0.033)	0.04	0.005 (0.072)	0.94
SAT (+10 cm <sup>2</sup> )	-0.007 (0.002)	0.003	-0.005 (0.005)	0.32
SM (+10 cm <sup>2</sup> )	0.014 (0.010)	0.18	0.027 (0.013)	0.03
IMAT (+10 cm <sup>2</sup> )	-0.053 (0.016)	0.001	-0.047 (0.023)	0.04
FMF <sup>^</sup> (+1%)	-0.011 (0.003)	<0.0001	-0.008 (0.004)	0.02

$\beta$  estimates with standard error (se) are listed.

\*Adjusted for pretest clinical score, nonwhite race, eGFR <60 ml/min/1.73 m<sup>2</sup>, LVEF, BMI, SAT, SM and IMAT or FMF.

BMI: body mass index; SAT: subcutaneous adipose tissue; SM: skeletal muscle; IMAT: intermuscular adipose tissue; FMF: fatty muscle fraction, IMAT/(SM+IMAT)\*100

<sup>^</sup>Every 1% increase in FMF was associated with a 2% increased odds of CMD, defined as CFR <2 [OR 1.02 (1.01-1.04), unadjusted p=0.008 and adjusted p=0.04]



**Table 3.** Multivariable-adjusted Associations of Thoracic Body Composition and CFR with Major Adverse Events

	Univariable		Model 1* (Traditional risk factors)		Model 2† (+Body composition)		Model 3‡ (+CFR)	
			Model statistic	P-value	Model statistic	P-value <sup>§</sup>	Model statistic	P-value <sup>§</sup>
Global Chi-square			26.8	Ref.	65.4	<0.001	74.5	<0.001
AIC			1157		1129		1121	
Variable	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Pretest clinical score	1.09 (1.04-1.15)	<0.001	1.09 (1.03-1.15)	0.001	1.07 (1.01-1.13)	0.01	1.06 (1.01-1.12)	0.03
Nonwhite race	0.99 (0.66-1.47)	0.95	0.97 (0.65-1.44)	0.86	1.16 (0.77-1.74)	0.48	1.20 (0.80-1.80)	0.38
eGFR<60 ml/min/1.73 m <sup>2</sup>	1.99 (1.15-3.45)	0.01	1.56 (0.89-2.74)	0.12	1.37 (0.78-2.40)	0.27	1.43 (0.82-2.50)	0.21
LVEF (+10%)	0.69 (0.56-0.86)	0.001	0.70 (0.56-0.87)	0.001	0.72 (0.57-0.89)	0.003	0.70 (0.56-0.87)	0.001
BMI (+10 kg/m <sup>2</sup> )	0.90 (0.69-1.18)	0.46	0.89 (0.67-1.18)	0.42	1.08 (0.60-1.95)	0.80	1.06 (0.58-1.92)	0.85
SAT area (+10 cm <sup>2</sup> )	0.98 (0.96-1.00)	0.078			0.94 (0.91-0.98)	0.003	0.94 (0.91-0.98)	0.003
SM area (+10 cm <sup>2</sup> )	0.98 (0.90-1.10)	0.60			0.88 (0.80-0.96)	0.006	0.89 (0.81-0.97)	0.01
IMAT area (+10 cm <sup>2</sup> )	1.21 (1.09-1.35)	<0.001			1.59 (1.35-1.86)	<0.001	1.53 (1.30-1.80)	<0.0001
Coronary flow reserve (-1U)	1.81 (1.28-2.56)	0.001					1.78 (1.23-2.58)	0.002
							+Interaction (IMAT*CFR)	0.02
Fatty muscle fraction (+1%)	1.04 (1.02-1.06)	<0.0001			1.07 (1.05-1.10)	<0.001	1.07 (1.04-1.09)	<0.001
							+Interaction (FMF*CFR)	0.04

Major adverse events include death and hospitalization for nonfatal myocardial infarction or heart failure.


\*Adjusted for pretest clinical score (includes age, sex, hypertension, dyslipidemia, diabetes, family history of premature CAD, tobacco use, anginal symptoms, estrogen status and presence of BMI $\geq$ 27 kg/m<sup>2</sup>), race, BMI, eGFR and LVEF.

† Adjusted for pretest clinical score, race, BMI, eGFR, LVEF and body composition metrics (SAT, SM, IMAT or FMF).



‡ Adjusted for pretest clinical score, race, BMI, eGFR, LVEF, body composition metrics (SAT, SM, IMAT or FMF) and CFR (-1U).

§ P-value for likelihood ratio test between sequential models.


CFR: coronary flow reserve; BMI: body mass index; eGFR: estimated glomerular filtration rate; LVEF: left ventricular ejection fraction; SAT: subcutaneous adipose tissue; SM: skeletal muscle; IMAT: intermuscular adipose tissue; FMF: Fatty muscle fraction; HR: hazard ratio; CI: confidence interval



**Figure 1.** Thoracic body composition compartments and relationship to body mass index, BMI. (A) Distribution of BMI in the study population. (B) Example of CT slice selection at the twelfth thoracic vertebra (T12) level and segmentation of subcutaneous adipose tissue (SAT, green), skeletal muscle (SM, blue) and intermuscular adipose tissue (IMAT, red) areas. Relationship between BMI and SAT (C), SM (D), and IMAT (E).

<b>Age</b>	<b>50-55 years</b>	<b>50-55 years</b>
<b>Sex</b>	<b>Female</b>	<b>Female</b>
<b>Race</b>	<b>Hispanic</b>	<b>Hispanic</b>
<b>BMI</b>	<b>35.5 kg/m<sup>2</sup></b>	<b>36.3 kg/m<sup>2</sup></b>
	 <p><b>A</b></p> <p><b>SAT</b> 304.5 cm<sup>2</sup>  <b>SM</b> 89.5 cm<sup>2</sup>  <b>IMAT</b> 14.1 cm<sup>2</sup></p>	 <p><b>B</b></p> <p><b>SAT</b> 239.8 cm<sup>2</sup>  <b>SM</b> 110.8 cm<sup>2</sup>  <b>IMAT</b> 29.8 cm<sup>2</sup></p>
<b>CFR</b>	<b>2.4</b>	<b>1.4</b>


**Figure 2:** Characterization of thoracic body composition at the twelfth thoracic vertebra (T12) level in representative patients (A, B) of similar age, sex, race and BMI with normal renal function, LVEF and myocardial perfusion. Relative to patient (A), patient (B) demonstrated decreased SAT and increased SM and IMAT areas, also with CFR <2, consistent with CMD. BMI: body mass index; LVEF: left ventricular ejection fraction; SAT: subcutaneous adipose tissue; SM: skeletal muscle; IMAT: intermuscular adipose tissue; CFR: coronary flow reserve; CMD: coronary microvascular dysfunction



**Figure 3.** Unadjusted (A, C) and adjusted (B, D) freedom from major adverse events by CMD and obesity (A, B) or IMAT median (C, D). Major adverse events include death and hospitalization for nonfatal myocardial infarction or heart failure. CMD: coronary microvascular dysfunction, coronary flow reserve <2; obesity, body mass index  $\geq 30$ ; IMAT: intermuscular adipose tissue, high  $\geq 11.5 \text{ cm}^2$

\*Adjusted for pretest clinical score, race, estimated glomerular filtration rate <60, left ventricular ejection fraction, skeletal muscle and subcutaneous adipose tissue areas

† p-value refers to interaction between coronary flow reserve and IMAT continuous variables



**Figure 4.** Adjusted annualized rate of major adverse events by CMD and obesity (A) or IMAT median (B). Major adverse events include death and hospitalization for nonfatal myocardial infarction or heart failure. Poisson regression was adjusted for pretest clinical score, skeletal muscle and subcutaneous adipose tissue areas. CMD: coronary microvascular dysfunction, coronary flow reserve <2; obesity, body mass index  $\geq 30$ ; IMAT: intermuscular adipose tissue, high  $\geq 11.5 \text{ cm}^2$


## **Supplemental Materials**



**Table S1:** Patients Meeting the Clinical Endpoint


<b>Outcome</b>	<b>Patients, n (%) (N=669)</b>
Total major adverse events	98 (14.6%)
Death	54 (8.1%)
Hospitalization for myocardial infarction	33 (4.9%)
Hospitalization for heart failure	34 (5.1%)

Median follow-up time was 5.8 (3.2-7.1) years. Time to first event was used for analysis.



**Figure S1.** Study flowchart.

CAD: coronary artery disease; HF: heart failure; PET: positron emission tomography; CT: computed tomography; SSS: summed stress score; LVEF: left ventricular ejection fraction; T12: twelfth thoracic vertebra



**Figure S2.** Spearman's correlations between measures of BMI and thoracic body composition,  $p < 0.005$  for all.

BMI: body mass index; SAT: subcutaneous adipose tissue; IMAT: intermuscular adipose tissue; SM: skeletal muscle; FMF: fatty muscle fraction,  $IMAT / (SM + IMAT) * 100$